Selection of currently ongoing clinical pharmaceutical trials at the NCRC

Multiple Sclerosis studies / MOGAD:

Title	Link to the public register	Recruitment status
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES)	NCT04411641	finished
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)	NCT04458051	finished
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab as monotherapy or in addition to baseline therapy in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)	NCT05271409	active
A Randomized, double-blind, Placebo-controlled, multicenter Phase 3 pivotal study to evaluate the efficacy and safety of rozanolixizumab to treat adult patients with Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)	NCT05063162	active

Myasthenia gravis studies:

Titel	Link to the public register	Recruitment status
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis	NCT05403541	active
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis (ADAPTSC+)	NCT04818671	active
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis	NCT04951622	active
A Phase 3B, Randomized, Open-label, Parallel-Group Trial to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis (ADAPT NXT)	NCT04980495	active
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	NCT05556096	active
A Phase 3, multinational, randomized, double-blind, placebo-controlled trial to examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis (NIMBLE)	NCT05070858	active

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) studies:

Title	Link to the public register	Recruitment status
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP	NCT05581199	active